The story of Sildenafil presents a nuanced case for stakeholders in the drug sector. While initially a tremendous success, generating billions, the patent lapse and the subsequent flood of cheaper competitors have https://pharma380799.csublogs.com/49693521/the-little-copyright-and-big-pharma-a-risky-play